Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.51 |
| ▸ | KDR | P35968 | 5/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.44 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.44 |
| ▸ | IDH1 | O75874 | 4/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | LTK | P29376 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | CDK8 | P49336 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31212719 | 0.89 | KDR (0.61) | PDGFRBKDRCA1CA2CA9 | |
| SCHEMBL57825 | 0.89 | KDR (0.61) | PDGFRBKDRCA1CA2CA9 | |
| SCHEMBL58537 | 0.88 | CHRNA7 (0.51) | MEN1KMT2AMAPTPDGFRBKDR | |
| SCHEMBL2236665 | 0.87 | KDR (0.49) | MEN1KMT2AMAPTHTTRAB9A | |
| SCHEMBL2240127 | 0.86 | RAF1 (0.53) | MEN1KMT2AMAPTHTTPDGFRB | |
| SCHEMBL12346305 | 0.85 | KDR (0.50) | MEN1KMT2AMAPTHTTRAB9A | |
| SCHEMBL423370 | 0.85 | MAPT (0.59) | MEN1KMT2AMAPTHTTRAB9A | |
| SCHEMBL19067997 | 0.85 | PDGFRB (0.55) | MEN1KMT2AMAPTHTTRAB9A | |
| SCHEMBL2237877 | 0.84 | KDR (0.47) | MEN1KMT2AMAPTHTTRAB9A | |
| SCHEMBL2238649 | 0.83 | CYP1A2 (0.56) | MEN1KMT2AMAPTHTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190337-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A.. (FR) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190337-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | DPYD, TYMP, PCK2 | MEN1 2411/4885KMT2A 3981/4885MAPT 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.